Anastrozole vs HCG
A side-by-side research comparison of Anastrozole and HCG across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | HCG |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Human Chorionic Gonadotropin |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | FDA Approved |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Binds LH/CG receptors on Leydig cells, stimulating intratesticular testosterone synthesis and maintaining spermatogenesis via local paracrine signaling independent of pituitary FSH/LH. |
| Molecular weight | 293.37 Da | ~36,700 Da |
| Half-life | ~46.8 hours | ~33 hours |
| Bioavailability | ~80-85% oral | ~100% (subcutaneous/intramuscular) |
| Typical dose | 0.25-0.5 mg | 500-1000 IU |
| Frequency | 2-3x per week | 2-3x per week |
| Route | Oral tablet | Subcutaneous injection |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
HCG reported benefits
- Preserved testicular size
- Maintained fertility on TRT
- Intratesticular testosterone
- Improved mood (neurosteroid support)
- Pregnenolone/DHEA maintenance
Related comparisons
Research and educational reference only. Not medical advice.